< 1 minute read
May 9, 2023

A-1331852: A First-In-Class BCL-XL Inhibitor


first-in-class, bioavailable BCL-XL inhibitor oral efficacy in xenograft, led to ADC dev. from SBDD of prior BH3 mimetics ACS Med. Chem. Lett., Jul. 5, 2020 AbbVie, North Chicago, IL / Genentech


Molecules of the Month

MOTY Nominees

Molecule of the Year